Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01633112

MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone — ASSESS  

Relapsing-remitting Multiple Sclerosis (RRMS) Clinical Trial

Official title:
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Clinical Trial Summary

The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS

Clinical Trial Description

This was a multicenter, randomized, rater- and dose-blinded, study to compare the efficacy and safety of 0.25 mg and 0.5 mg of fingolimod with glatimer acetate 20 mg s.c. in patients with RRMS.

This study consisted of 3 periods:

- Screening Period: up to 45 days for all patients

- Treatment Period: 12 months of glatiramer acetate 20 mg, fingolimod 0.25 mg, or fingolimod 0.5 mg

- Follow-up occurred 3 months (12 weeks) after the last dose of study drug for all patients The informed consent form was signed prior to any study related activities at the screening visit. Randomization to either treatment group was preformed at visit 1 after a diligent check of applicable in- and exclusion criteria in a 1:1:1 ratio (changed to 5:3:2 after implementation of Amendment 2 in 2015).

Treatment groups:

- fingolimod 0.5 mg/day orally for up to 12 months

- fingolimod 0.25 mg/day orally for up to 12 months

- glatiramer acetate 20 mg/day subcutaneously for up to 12 months ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01633112
Study type Interventional
Source Novartis
Contact
Status Terminated
Phase Phase 3
Start date August 9, 2012
Completion date April 30, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05177523 - Imaging the Interplay Between Axonal Damage and Repair in Multiple Sclerosis
Withdrawn NCT05172466 - Sensation, Motion, and Quality of Life on Natalizumab and Off Natalizumab N/A
Completed NCT05304520 - A Study for Tysabri Participant Preference
Completed NCT04115488 - Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri® Phase 3
Recruiting NCT06430671 - Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis Phase 1/Phase 2
Recruiting NCT05811416 - A Study to Describe the Persistence With Ozanimod Treatment in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants
Active, not recruiting NCT03846219 - MRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS) Phase 2
Completed NCT02587065 - Plegridy Satisfaction Study in Participants Phase 4
Not yet recruiting NCT02568111 - Brimonidine Tartrate for the Treatment of Injection Related Erythema Phase 4
Completed NCT01738347 - Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS). Phase 1
Terminated NCT02881567 - Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab Phase 3
Not yet recruiting NCT05245344 - Effects of Ozanimod on Immune-mediated Mechanisms of Neurodegeneration in Multiple Sclerosis - a Preclinical Study